Wednesday broker round-up
(Sharecast News) - Learning Technologies Group: Canaccord upgrades to buy with a target price of 150p.

(Sharecast News) - Learning Technologies Group: Canaccord upgrades to buy with a target price of 150p.
* European stocks fall for second straight session* Wall Street futures rise* Centamin shares down 20% after production update* Construction sector dips 1.5%, real estate down 1.6% Welcome to the home for real-time coverage of markets brought to you...
* European stocks fall for second straight session* Centamin shares down 20% after production update* Construction sector dips 1.5%, real estate down 1.6% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You...
* European stocks fall for second straight session* Centamin shares down 20% after production update* Construction sector dips 1.6%, real estate down 1.7% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You...
* European stocks fall for second straight session* Centamin shares down 20% after production update* Construction sector dips 1.5% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your though...
* European stocks fall for second straight session* Centamin shares down 20% after production update* Construction sector dips 2.3% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your though...
* European stock futures up 0.2%* Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.comON THE RADAR: IBERDROLA UNIT MERGER, AKZO NOBEL, ...
FRANKFURT, Oct 21 (Reuters) - GlaxoSmithKline said it would move its experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing, encouraged by mid-stage tr...
Glaxo's ViiV Gets Vocabria Boost From European Regulator
* Favourable immune response in mice, monkeys for vaccine* Human clinical trial expected to begin in fourth quarterBy Matthias BlamontPARIS, Oct 15 (Reuters) - Clinical trials of an experimental vaccine against COVID-19 which is being developed by F...
UK BROKER RATINGS SUMMARY: Berenberg Upgrades TalkTalk To Hold
UK BROKER RATINGS SUMMARY: National Express Made "ESG Top Pick"
* Thousands of staff seen at risk of undetected infection - union* Some banks ask staff to store phones away to prevent data leaks* Govt advises NHS app should be paused if phone not on person (Adds Department of Health comment)By Iain Withers an...
* Thousands of staff seen at risk of undetected infection - union* Some banks ask staff to store phones away to prevent data leaks* Govt advises NHS app should be paused if phone not on person (Adds TSB comment)By Iain Withers and Sinead CruiseLO...
(Sharecast News) - US drug giant Eli Lilly's monoclonal antibody treatment is effective in reducing levels of the novel coronavirus in patients and appears to be able to keep them from having to go go the emergency room or hospital, the company said.